Most Read News

The contract is for executing KAVACH, an indigenous train collision avoidance system, in 778 route kilometers in the Bengaluru and Mysuru divisions.

EBITDA increased 20.3% to ₹191.7 crore in the March 2025 quarter from ₹159.4 crore a year ago.

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

This latest order enlarges TCS’s continued engagement with BSNL to modernise the state-run telecom operator’s mobile infrastructure.

Headline CPI drops. There’s more to the story as core CPI remains elevated. Will RBI continue its accommodative stance as widely expected?

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

The issue may be done through public offers or private placements. This subject to market conditions, and regulatory approvals, stated the public lender.

Here are some of the stocks that may see significant price movement today.

Most of the IPO proceeds will be used for deleveraging, allowing for better margins and financial flexibility.

The company also said that its board has recommended a final dividend of ₹1.5 per equity share for the FY25.